Prognostic and clinicopathological significance of kinesin family member C1 in various cancers
Open Access
- 1 October 2019
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 98 (40), e17346
- https://doi.org/10.1097/md.0000000000017346
Abstract
Background: Kinesin family member C1 (KIFC1), a C-type kinesin motor protein, plays important roles in centrosome assembly and intracellular transport. Numerous studies have focused on the prognostic value of KIFC1 in malignant tumors and the relationship between KIFC1 expression and clinicopathological traits of cancer patients, but the studies remain controversial. And no meta-analysis has yet shown the association between KIFC1 and various cancers. Methods: Systematic retrieval was carried out within several databases, including PubMed, Embase, Web of Science, Wanfang and China National Knowledge Infrastructure (CNKI). In addition, hazard ratios (HR) and relative risks (RR) with 95% confidence intervals (CIs) were calculated to examine the risk or hazard correlation by Stata SE15.1. Results: Eleven studies with the overall 2424 participants were included in this research. High KIFC1 expression was remarkably correlated with worse OS (HR= 1.33, 95% CI= 1.07-1.60) and poorer relapse-free survival (HR= 2.28, 95% CI= 1.75-2.80). In subgroup analysis, high KIFC1 expression was a negative predictor for OS in patients with ovarian cancer (P<.001), breast cancer (P<.001), hepatocellular carcinoma (P<.001), and non-small cell lung cancer (P<.001), but not for esophageal squamous cell carcinoma (P=.246). Moreover, high levels of KIFC1 were related with positive lymph node metastasis (RR= 1.23, 95% CI= 1.011.50, P=.041) and advanced tumor node metastasis (TNM) stage (RR= 1.55, 95% CI= 1.27-1.89, P<.001). Conclusions: KIFC1 overexpression indicates poor prognosis and more serious clinicopathological characteristics in kinds of malignancies. Thus, we conclude that KIFC1 could be a target for clinical diagnosis and treatment of various cancers.Keywords
Funding Information
- National Natural Science Foundation of China (81860420 and 81760438)
This publication has 30 references indexed in Scilit:
- KIFC1 is a novel potential therapeutic target for breast cancerCancer Biology & Therapy, 2015
- Kinesin, 30 years later: Recent insights from structural studiesProtein Science, 2015
- Cancer treatment and survivorship statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- KIFCI, a novel putative prognostic biomarker for ovarian adenocarcinomas: delineating protein interaction networks and signaling circuitriesJournal of Ovarian Research, 2014
- Design, Synthesis, and Biological Evaluation of an Allosteric Inhibitor of HSET that Targets Cancer Cells with Supernumerary CentrosomesCell Chemical Biology, 2013
- Discovery and Mechanistic Study of a Small Molecule Inhibitor for Motor Protein KIFC1ACS Chemical Biology, 2013
- Overexpression of Kinesins Mediates Docetaxel Resistance in Breast Cancer CellsCancer Research, 2009
- The Expression of Three Genes in Primary Non–Small Cell Lung Cancer Is Associated with Metastatic Spread to the BrainClinical Cancer Research, 2009
- Kif5B and Kifc1 Interact and Are Required for Motility and Fission of Early Endocytic Vesicles in Mouse LiverMolecular Biology of the Cell, 2007
- Purification and Characterization of Native Conventional Kinesin, HSET, and CENP-E from Mitotic HeLa CellsOnline Journal of Public Health Informatics, 2001